Yat Sun Or - Feb 12, 2025 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Chief Scientific Officer
Signature
/s/ Matthew Kowalsky as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Feb 12, 2025
Transactions value $
-$24,171
Form type
4
Date filed
2/14/2025, 04:40 PM
Previous filing
Dec 10, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Award $0 +9.75K +2.64% $0.00 379K Feb 12, 2025 Direct F1
transaction ENTA Common Stock Tax liability -$24.2K -4.32K -1.14% $5.59 375K Feb 12, 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025.
F2 Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards.